Generic anticancers lift Nippon Kayaku
This article was originally published in Scrip
Executive Summary
There was again strong growth for Nippon Kayaku's generic anticancers in the fiscal year to May 31st, when paclitaxel became the top product in the diversified Japanese firm's pharma business.